Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility. (Pomegranate)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01918163|
Recruitment Status : Unknown
Verified July 2013 by Hillel Yaffe Medical Center.
Recruitment status was: Not yet recruiting
First Posted : August 7, 2013
Last Update Posted : August 7, 2013
Some animal studies revealed that the pomegranate juice may improve sperm quality in terms of concentration, motility and morphology, as well as in fertilization rate.
Minor data is available regarding the influence on male sperm.
|Condition or disease||Intervention/treatment||Phase|
|Male Infertility With Severe Oligo-terato-asteno-spermia||Dietary Supplement: Pomegranate pills||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||55 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.|
|Study Start Date :||September 2013|
|Estimated Primary Completion Date :||September 2014|
|Estimated Study Completion Date :||September 2014|
No Intervention: No Pills
Patients in this group will not receive Pomegranate pills.
Active Comparator: Pomegranate pills
The reccruited patient will receive pomegranate pills every day for 12 weeks. The control group will not be exposed for the pills.
|Dietary Supplement: Pomegranate pills|
- pregnancy [ Time Frame: 24 month ]
- ROS (reactive oxidative stress )and Interleukins level in semen fluid [ Time Frame: 12 weeks ]The unit for measure the ROS are Micromolar epicatechin equivalent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01918163
|Contact: Einat Shalom-Paz, MDemail@example.com|
|Contact: Ellenbogen Adrian, MDfirstname.lastname@example.org|
|Hillel Yaffe Medical Center||Not yet recruiting|
|Hadera, Israel, 38100|
|Contact: Reuma Barkan 97246304223 email@example.com|
|Principal Investigator:||Einat Shalom-Paz, MD||Hillel Yaffe Medical center, IVF unit, Hadera, Israel|